News

Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test

ARESupa test aims at broad detection of microbial infections employing next-generation sequencing and artificial intelligence Curetis explores venture capital (VC) funding for Ares Genetics while assessing all strategic and tactical financing options for growth of Unyvero core business Amsterdam, the Netherlands, Holzgerlingen, Germany, and Vienna, Austria, September 04, 2018, 01:00 am EST – Curetis N.V.…

Read More

Epigenomics Posts 88 Percent Increase in Q2 Revenues

Aug 08, 2018  NEW YORK (GenomeWeb) — Epigenomics reported today an 88 percent year-over-year increase in second quarter revenues amid strong growth in product sales and higher licensing income. For the three-month period ended June 30, Epigenomics’ revenues rose to €462,000 ($535,912) from €246,000 in the same period last year. Product sales — which include…

Read More

Epigenomics AG: Liquid Biopsy Test for Liver Cancer Detection to Obtain CE Mark

– Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2019 – Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 – Epigenomics AG (FSE: ECX,…

Read More

Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge

UTI panel covers 103 diagnostic targets 443-patient multi-center study demonstrates overall weighted average sensitivity of 95.6% at an overall weighted average specificity of 99.3%.  Amsterdam, the Netherlands; San Diego, CA, USA; and Holzgerlingen, Germany; April 19, 2018, 01:00 EDT — Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level…

Read More

Curetis Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority

– Second market authorization for Unyvero Cartridges this year in Singapore Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 04, 2018; published at 11:30 am CEST — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Acumen Research Laboratories Pte. Ltd. (Acumen), its partner for…

Read More

Curetis Subsidiary Ares Genetics Wins Incubator Stay in Silicon Valley

– Award winner in “GoSiliconValley” competition by Austrian Economic Chambers – Support for business development in U.S. market Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, March 06, 2018, 06:00 am EST – Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic…

Read More

Curetis Expects Near Term Decision by FDA Approving First Product in US

16 Feb 2018 – CEO Oliver Schacht from Curetis (EN Amsterdam:CURE) tells Proactive Investors their Unyvero Platform finds killer bugs in hospitals and tells doctors which antibiotics to use. Schacht says they expect the FDA to approve the platform and first product in the U.S. which is a test for life-threatening ammonia. Schacht says he…

Read More

Curetis Unyvero Hospitalized Pneumonia Application Receives Singapore Health Sciences Authority Approval

– Market authorization paves way for broader Unyvero commercial roll-out in ASEAN region through partner Acumen Research Laboratories – Near-term clinical validation study of first cartridge-based molecular test for Sepsis Host Response panel licensed from Acumen in preparation Amsterdam, the Netherlands, and Holzgerlingen, Germany, February 06, 2018;  — Curetis N.V. (the “Company” and, together with Curetis…

Read More

Curetis Expects Near-Term FDA Decision on De Novo Request for Unyvero LRT

– Review of the Unyvero System and Lower Respiratory Tract (LRT) Cartridge is nearing completion – U.S. commercial team and operational infrastructure in place Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, January 08, 2018, 01:00 am EST – Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis”),…

Read More